Company Overview of Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK...
38 Sidney Street
Cambridge, MA 02139
Founded in 2007
Key Executives for Agios Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $500.0K
Principal Financial Officer and Senior Vice President of Finance
Total Annual Compensation: $309.0K
Chief Operating Officer
Total Annual Compensation: $375.0K
Chief Medical Officer
Total Annual Compensation: $371.4K
Chief Scientific Officer
Total Annual Compensation: $387.3K
Compensation as of Fiscal Year 2014.
Agios Pharmaceuticals, Inc. Key Developments
Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell 1000 Index
Jun 30 15
Agios Pharmaceuticals, Inc. has been added to Russell 1000.
Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell 2000 Index
Jun 29 15
Agios Pharmaceuticals, Inc. will be removed from Russell 2000 Index
Agios Pharmaceuticals, Inc. Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation
Jun 24 15
Agios Pharmaceuticals, Inc. announced dose administration for the first patient in a Phase 1, open-label, dose-escalation and expansion study of single agent AG-881, a small molecule that has shown in preclinical studies to fully penetrate the blood-brain barrier and inhibit isocitrate dehydrogenase-1 (IDH1) and IDH2 mutations in cancer models. The purpose of the Phase 1 multi-center, open-label study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced solid tumors. AG-881 will be administered continuously as a single agent dosed orally in a 28-day cycle. The first portion of the study includes a dose-escalation phase in which cohorts of patients will receive ascending oral doses of AG-881 to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose based on safety and tolerability. The second portion of the study is a dose expansion phase where patients will receive AG-881 to further evaluate the safety,
tolerability and clinical activity of the recommended Phase 2 dose. Upcoming Milestones for AG-881: A second dose-escalating and expansion trial, for patients with advanced IDH1 or IDH2 mutant-positive hematologic malignancies whose cancer has progressed on a prior IDH inhibitor therapy, is expected to begin shortly.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries